OBJECTIVE: To evaluate the efficacy of combination chemoimmunotherapy of @entity3118 , @entity786 and rituximab (FCR) in @entity1072 ( @entity1072 ). METHODS: Twenty-one @entity1 with @entity1072 were treated with FCR regimen which consisted of @entity3118 (25 mg/m(2), days 2 to 4), @entity786 (250 mg/m(2), days 2 to 4) and rituximab (375 mg/m(2), day 1) in a course of 28 days. The @entity41 ( @entity41 ) was determined by multiparameter flow cytometry. The correlation between the pretreatment characteristics and complete remission (CR) rate was analyzed. RESULTS: Eleven @entity1 (52.4%) achieved CR, 7 (33.3%) achieved partial remission (PR) with a overall response (OR) rate of 85.7%. With a median follow-up time of 19 (7 - 73) months, the overall survival (OS) was 86.0%, and the progression-free survival (PFS) was 72.0%. Pretreatment parameters independently associated with higher CR rates were Binet stage A + B, IgVH mutated and @entity6755 less than 20%. @entity41 was less than 1% in 6 @entity1 . The most common @entity137 were myelosuppression and @entity344 . CONCLUSION: FCR is an effective regimen for @entity1072 @entity1 .

[Efficacy of chemoimmunotherapy with @entity3118 , @entity786 and rituximab for XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'minimal residual disease'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'chronic lymphocytic leukemia'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal reaction'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity6755 :: ('7535', 'Gene') :: ['ZAP-70']
@entity1072 :: (MESH:D015451,Disease) :: ['chronic lymphocytic leukemia']
